

LIVING DRUGS

SAXONIAN PRECISION THERAPY CLUSTER

SaxoCell 2025

Cutting-Edge Cell and Gene Therapy from Saxony

Cell and Gene Therapies

The Future of treatment for genetic and aggressive tumor diseases




One-fits-all solution

Chemotherapy




- Chemical substances
- Regular intake
- Alleviation of symptoms
- Strong side effects
- Not patient-specific

LIVING DRUGS Gene and Cell Therapies



Game changer


Tailored treatment
for specific person & diagnosis



- ✓ **Targeted action** – Targeted attack on cancer cells
- ✓ **Usually a single application** - Healing not treating
- ✓ **Long-lasting effect** – Immune cells "remember" tumor
- ✓ **Fewer side effects** – Less damage to healthy cells
- ✓ **Personalized approach** – Adaptable to tumor profile

What are gene and cell therapies?

A brief overview



Technological principles


- Use of **immune cells** (T cells, NK cells, macrophages) and **stem cells**
- Use of modern **gene editing technologies**
- **Molecular modification & reprogramming** for:
 - Correction of genetic defects
 - Enhancement of the immune response
 - Replacement of damaged tissue

Advantages & potential

- Highly **personalized & effective** therapies
- New **hope for patients** with serious diseases
- **Pioneering alternative** to conventional treatments

→ **Goal:** Develop and optimize **safe, effective, and cost-efficient gene and cell therapies**

- Focus on "**living drugs**" to revolutionize treatments
- Strong **network of local partners** from academia, healthcare, and industry
- Positioning Saxony as a **leading hub for gene and cell therapy**



Core partners of the cluster

- **2 Universities** (TUD, ULEI)
- **1 Research Institute** (Fh IZI)
- **3 Hospitals** (Chemnitz, UKL, UKD)
- **23 Industrial partners**



- **Winner of the BMBF's Clusters4Future initiative**
- Selected nationwide from **137 competitors**
 - **3 potential funding phases (3 years each)**
 - Currently 2nd funding phase started
- **Long-term sustainability** initiated through **SaxoCell e.V.**




The future clusters of the 1st competition round



SaxoCell – achieving more together

The R&D projects




SaxoCell – achieving more together

SaxoCellutions as the innovation interface



SAXOCELLUTIONS - SaxoCell provides solutions

The infrastructure project in the cluster



SaxoCell successes

The current achievements from the cluster



Scientific Breakthroughs



First successful antibody production at Fraunhofer IZI (S1 GMP facility) in 2024



Further development of the Designer recombinase technology

Clinical Studies

ROR2 CAR-T - Fh IZI & UK Würzburg

Clinical study with ROR2-specific CAR-T cells in patients with ROR2+ tumors

UC-CISSII – TU Dresden & Canadian centers

MSCs from the umbilical cord as cellular immunotherapy for septic shock

Patents

17 new patent applications

6x macrophages, 5x genome editing, 2x NK cells, 1x T cells, 3 others

Additional Funding

GO·Bio

GEFÖRDERT VOM




xMac / AlloMac – **1mio€**

UltraCART / SB-TRACT – **9mio€**


SaxoCell Forums

SaxoCell®
meets Politics

SaxoCell®
Investors Club



Networking of politics & healthcare



Presentation of Saxon business ideas to investors

Spin-offs & Settlements

3 Spin-offs




2 Settlements



The faces of SaxoCell

Saxocell speakers & the consortium



The SaxoCell speakers from left to right: **Ulrike Köhl** (Director of both Fraunhofer IZI & Institute for Clinical Immunology, Leipzig University), **Frank Buchholz** (UCC Medical Systems Biology, TUD), **Martin Bornhäuser** (Medical Clinic I, Carl Gustav Carus University Hospital Dresden & NCT & UCC Dresden)

The SaxoCell consortium at our Kick-off Meeting for the 2nd Funding phase in January 2025 at Fraunhofer IZI



Get in touch with us!

SaxoCell contacts, info and socials



E-Mail: info@saxocell.de



Website



Industry Flyer

Socials



LinkedIn



Instagram



YouTube